Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A series of combretastatin A-4 analogs derived from the ATP competitive, VEGF receptor tyrosine kinase inhibitor, SU5416 were synthesized. The cytotoxic effects of the analogs were evaluated against PC-3 and MDA-MB-231 cancer cell lines, as well as their abilities to inhibit tubulin polymerization. Results are compared to those of compound 1, our lead compound previously reported.

Original publication




Journal article


Bioorg Med Chem

Publication Date





6492 - 6501


Antineoplastic Agents, Phytogenic, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Chromatography, High Pressure Liquid, DNA, Neoplasm, Drug Screening Assays, Antitumor, Female, Humans, Indoles, Isomerism, Magnetic Resonance Spectroscopy, Molecular Conformation, Podophyllotoxin, Pyrroles, Stilbenes, Structure-Activity Relationship, Tubulin